Company Website:
http://www.iderapharma.com/
CAMBRIDGE, Mass. -- (Business Wire)
Idera Pharmaceuticals (NASDAQ: IDRA) today announced that Sudhir
Agrawal, D. Phil., Chairman and Chief Executive Officer of Idera, will
present a company overview at the Cowen and Company 32nd
Annual Healthcare Conference on March 7th 2012, at 10:00 am
EST in Boston, Massachusetts.
A live audio webcast of the presentation will be available in the
Investor section of Idera's website: www.iderapharma.com.
An archived version will also be available on the Company's website
after the event for a limited time.
About Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals applies its proprietary Toll-like Receptor (TLR)
drug discovery platform to create immunomodulatory drug candidates. The
Company's TLR-targeted candidates are being developed to treat
autoimmune and inflammatory diseases and cancer, and for use as vaccine
adjuvants. Additionally, the Company is advancing its gene-silencing
oligonucleotide (GSO) technology for the purpose of inhibiting the
expression of disease-promoting genes. For more information, visit http://www.iderapharma.com.
Contacts:
Idera Pharmaceuticals, Inc.
Lou Arcudi, 617-679-5517
larcudi@iderapharma.com
or
MacDougall
Biomedical Communications
Chris Erdman, 781-235-3060
cerdman@macbiocom.com
Source: Idera Pharmaceuticals, Inc.
© 2026 Canjex Publishing Ltd. All rights reserved.